1. Home
  2. ASRT vs LUNG Comparison

ASRT vs LUNG Comparison

Compare ASRT & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Assertio Holdings Inc.

ASRT

Assertio Holdings Inc.

HOLD

Current Price

$0.77

Market Cap

69.2M

Sector

Health Care

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$2.01

Market Cap

63.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASRT
LUNG
Founded
1995
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Specialties
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
69.2M
63.6M
IPO Year
1997
2020

Fundamental Metrics

Financial Performance
Metric
ASRT
LUNG
Price
$0.77
$2.01
Analyst Decision
Strong Buy
Buy
Analyst Count
1
7
Target Price
$3.00
$6.81
AVG Volume (30 Days)
755.4K
1.1M
Earning Date
11-10-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$137,354,000.00
$91,664,000.00
Revenue This Year
N/A
$9.21
Revenue Next Year
N/A
$5.03
P/E Ratio
N/A
N/A
Revenue Growth
9.22
15.59
52 Week Low
$0.51
$1.31
52 Week High
$1.04
$9.37

Technical Indicators

Market Signals
Indicator
ASRT
LUNG
Relative Strength Index (RSI) 49.01 59.51
Support Level $0.65 $1.57
Resistance Level $0.79 $1.74
Average True Range (ATR) 0.04 0.15
MACD 0.01 0.06
Stochastic Oscillator 84.21 81.40

Price Performance

Historical Comparison
ASRT
LUNG

About ASRT Assertio Holdings Inc.

Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: